Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a Canada-based patient-driven medical device company that provides healthcare solutions for advanced wound care, infection control, and medical device coatings. The Company's solutions are designed for patients and made for care providers. The Company leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon's name, and by developing and commercializing medical products for other medical companies under development and license contracts. The Company has three proprietary platform technologies that have the potential to be developed into a number of medical devices and products: Collagen matrix, Antimicrobial silicone adhesive and Medical coatings. Its product type includes advanced wound care, antimicrobial dressings, collagen dressings, IV dressings, and perioperative dressings. Its brands include ColActive PLUS, CovaClear, CovaView, CovaWound, IV Clear, SurgiClear, and VALGuard.


TSXV:COV - Post by User

Bullboard Posts
Post by zenvestingon May 11, 2016 1:20pm
101 Views
Post# 24862591

Clinical editor of WOUNDS presenting for COV!

Clinical editor of WOUNDS presenting for COV!COV.v: Today's PR might not strike you as a big deal, it doesn't look like much more than another conference appearance, but when I Google'd the name of the guy hosting the Symposium, I am once again impressed that we have a company with leading edge technologies, trading at a huge discount to it's more respected "peers" in the industry. Dr. Terry Treadwell is no slouch, he is the Clinical Editor of the WOUNDS Journal, the most widely read journal focussing on wound care. https://www.woundsresearch.com/content/editorial-board WOUNDS is the most widely read, peer-reviewed journal focusing on wound care and wound research. The information disseminated to our readers includes valuable research and commentaries on tissue repair and regeneration, biology and biochemistry of wound healing, and clinical management of various wound etiologies. I take it as a very positive sign that a guy that is chief editor for the leading wound care journal is presenting on our behalf. I maintain my position that this is a high quality, undiscovered name in this industry that deserves a valuation similar to that of DSCI, ALQA, MDWD, etc.. Someone has sold off this stock again the past few days, I think they created I nice entry opportunity in the short term. The company just began scheduling earnings calls last quarter.....I don't think they did this to discuss lackluster results....we know the middle East tenders present big opportunities.....I do think this could be a break out year ahead for the company.....can't wait to see results at month end!
Bullboard Posts